February 19th 2025
Chemomab completed an end-of-phase 2 meeting with the FDA and has aligned on the design of a phase 3 registration study for nebokitug (CM-101) in PSC.
February 17th 2025
Experts' Perspectives: How to Address a Lack of Diversity in Clinical Trials
March 1st 2024In the final part of our 3-part series, our panel of experts discuss what their fields and its leaders could do to make sure this lack of diversity in trials does not continue. These responses are highlighted in the following video and transcribed below.
Experts' Perspectives: How Lack of Trial Diversity Impacts Treatment Development
March 1st 2024In part 2 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our second question, which addresses how the previously established lack of diversity in clinical trials has had a direct effect on the development and application of new therapies or devices in real-world settings.
Experts' Perspective: How a Historic Lack of Diversity Manifests in Real-World Care
March 1st 2024In part 1 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our first question, which sought to encapsulate the perspectives of our group of experts on how a historic lack of diversity in clinical trials has manifested itself in today’s care of patients from diverse backgrounds.
Hepatology Month in Review: January 2024
February 3rd 2024The editorial team’s monthly recap of the top news in hepatology features research emphasizing women’s health in liver disease, a look at some less-recognized health benefits associated with achieving SVR, and promising approaches for preventing and treating hepatic conditions.
Women With Alcohol-Related Liver Disease Face Greater Risk of Mortality Than Men
January 30th 2024Although there was a greater prevalence of ALD and MetALD among male study participants, females had a greater risk of mortality from both SLD phenotypes, highlighting a potentially greater impact of alcohol consumption on women with liver disease than men.
Pregnant Women in Rural Regions Face Greater HCV, Preterm Birth Burden
January 26th 2024Results showed a 12% incidence of HCV in pregnancy with a preterm birth rate nearly double the national average, although no statistically significant difference in preterm birth rates was observed between HCV-positive and HCV-negative patients.
Achieving SVR Reduces Risk of Cardiovascular Events in Patients with HCV
January 23rd 2024Results highlight the benefit of achieving sustained virological response with DAAs for decreasing patients’ risk of carotid atherosclerosis and peripheral artery disease, especially among those with severe fibrosis.